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Abst rac t
Introduction: Kidney transplant (KTx) patients on immunosuppressive therapy are predisposed to the development 
of infections and cancers. 
Aim: To compare the incidence and type of malignant skin lesions in kidney transplant patients and the dialyzed 
population based on the initiated dermatologic screening.
Material and methods: The study included 598 patients: 486 kidney transplant recipients and 112 patients on main-
tenance dialysis. All the patients underwent dermatological examination. Only histologically confirmed cancers were 
included in this study. Age, gender and immunosuppressive therapy administration were also considered. Patients 
were followed up by a dermatologist for a period of 5 years.
Results: Fifty-eight skin cancers; 39 basal cell carcinomas (BCC), 13 squamous cell carcinomas (SCC), 1 Bowen 
disease, 2 Kaposi sarcoma, 1 malignant melanoma, 1 Merkel cell carcinoma, and 1 fibrosarcoma protuberans were 
diagnosed in 30 (6.2%) kidney transplant patients, and 8 lesions (7 BCC and 1 SCC) were found in 4 (3.6%) patients 
on dialysis. 
Conclusions: The initiated dermatologic screening program indicates that the risk of skin cancer incidence in post 
kidney transplant patients receiving immunosuppressive therapy was significantly higher than in patients on dialysis. 
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Introduction
The population of kidney transplant (KTx) recipients 
is particularly vulnerable to the development of infec-
tious complications and tumors due to the prolonged use 
of immunosuppressive drugs [1–3]. Skin tumors represent 
up to 50% of all malignancies and their incidence is de-
pended on the geographic region and increases with time 
from transplantation [4–7]. According to the available lit-
erature, the most commonly occurring skin cancers are 
squamous cell carcinoma (SCC) and basal cell carcinoma 
(BCC), known collectively as non-melanoma skin cancers 
(NMSC). In post-transplantation patients, the risk of BCC 
is 10 times higher and the risk of SCC is up to 250 times 
higher than in the general population [8]. In case of ma-
lignant melanoma (MM), the corresponding risk is up to 
8 times higher [9], while for Kaposi’s sarcoma (KS) it is up 
to 20 times higher [10–12]. 
A limited amount of publications regarding the inci-
dence of malignancies in patients on dialysis and barely 
any comparative studies of this population to a group of 
kidney transplant recipients can be found in the available 
literature [13–15]. 
Aim
The study was aimed to compare the incidence as 
well as type of malignant skin lesions in KTx patients 
treated with immunosuppression and in patients on 
maintenance dialysis therapy based on the initiated der-
matologic screening program.
Material and methods
The study was conducted among a group of 598 pa-
tients on renal replacement therapy. A total of 486 pa-
tients: 296 (60.9%) men and 190 (39.1%) women aged 
46.0 ±13.1 years (range: 18–74 years) underwent KTx from 
a deceased donor. Within the analyzed group, 480 pa-
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tients have undergone one transplant, and 6 had two 
KTx. The mean time from the transplantation procedure 
to the time of the first dermatological examination was 
54.7 ±48.8 months (median: 42.5, range: 0–298 months). 
The most commonly used immunosuppressive 
regimens were the combinations including: cyclospori- 
ne A (CyA), mycophenolate mofetil (MMF) and steroids 
– 207 (42.5%) patients, tacrolimus (TAC) with MMF and 
steroids – 102 (20.9%), CyA with azathioprine (AZA) and 
steroids – 53 (10.9%) patients, CyA + steroids – 27 (5.6%), 
and TAC + steroids – 25 (5.1%). 
Acute rejection occurred in 85 (17.5%) patients. All of 
these 85 patients were treated with Solumedrol, while 
OKT3 and ATG were additionally used in 6 and 4 cases, 
respectively.
The dialysis group consisted of 112 patients: 57 
(50.9%) men and 55 (49.1%) women aged 57.4 ±15.4 
years (ranging: 22–91 years old) who have not received 
immunosuppressive therapy prior to dialysis. The average 
time from initial dialysis to dermatological examination 
was 63.2 ±74.0 months. Within this group, 87 (77.7%) 
patients were treated with hemodialysis (HD), while 25 
(22.3%) patients with peritoneal dialysis.
The study was approved by the Bioethics Commit-
tee of the Jagiellonian University (No. KBET/100/B/2006 
dated June 29, 2006).
During the first dermatological evaluation, the pa-
tient’s entire skin surface was carefully examined for all 
abnormalities. Only histologically confirmed cancers were 
included in the study. Patients were then followed up for 
a period of 5 years.
The study was retrospective-prospective. 
Statistical analysis
The obtained results were statistically analyzed using 
the Student’s t-test, Mann-Whitney, c2 and Fisher tests. 
In all of the above tests, the results were statistically sig-
nificant at p < 0.05. Statistical analysis was performed 
using the Statistica 9.0 software (StatSoft).
Results
In the study population of 486 KTx recipients, skin 
cancers were diagnosed in 30 patients (Table 1). The 
most commonly observed skin cancers were NMSC; 
overall 53 lesions were diagnosed (Table 2). Besides the 
NMSC we found 2 cases of Kaposi sarcoma, one Merkel 
cell carcinoma, one malignant melanoma and one fibro-
sarcoma protuberans. The ratio of BCC : SCC was 2.79, 
while the ratio of SCC : BCC equaled 0.36 – for the entire 
population of patients after KTx.
In the group of post-KTx patients, single tumors were 
present in 11/25 (44.0%) patients with NMSC – BCC in 
7/18 patients (38.9%), and SCC in 4/10 (40.0%) patients 
(p = 1.0).
Among the KTx recipients with NMSC, BCC was di-
agnosed in 15 (60%) of patients, SCC in 7 (28.0%), and 
3 (12.0%) patients had both types. 
In 5 patients, multiple skin lesions were diagnosed 
during a single visit, while in other cases, numerous 
changes were observed after an average of 24 months 
(range: 2–60 months).
Among the dialyzed group, only 8 NMSC were found 
in 4 (3.6%) patients. Three men and one woman were 
diagnosed to have 7 cases of BCC and one case of SCC 
(Table 2). Only single tumors were observed. The ratio of 
BCC : SCC was 7 : 1, and SCC : BCC = 0.14 for the entire 
population of patients on dialysis. All of these patients 
were treated with hemodialysis.
In both groups, NMSC were mainly localized on the 
face. The mean age at the time of the first skin cancer 
diagnosis was lower in KTx recipients than in dialysis 
therapy patients (59.0 ±8.4 vs. 66.0 ±8.5); however, the 
Table 1. Number and percentage of patients from both studied groups with consecutive skin cancers types
Type of changes Patients after transplantation
(N = 486)
Dialyzed patients  
(N = 112)
P-value* Odds ratio**  
(95% of confidence)
All skin cancers 30 (6.2%) 4 (3.6%) 0.3 6.65 (1.45–30.4)
NMSC: 25 (5.1%) 4 (3.6%) 0.5 6.64 (1.25–35.2)
BCC 18 (3.7%) 4 (3.6%) 0.9 6.22 (0.94–41.1)
SCC 10 (2.1%) 1 (0.9%) 0.7 5.42 (0.43–68.1)
Bowen disease 1 (0.2%) 0 – –
Merkel cell carcinoma 1 (0.2%) 0 – –
Malignant melanoma 1 (0.2%) 0 – –
Kaposi sarcoma 2 (0.4%) 0 – –
Fibrosarcoma protuberans 1 (0.2%) 0 – –
*c2 test (df = 1), **odds ratio for transplant and dialysis patients.
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KTx recipients were younger and the observed differ-
ences were not statistically significant (p = 0.14). The 
majority of the NMSC lesions in KTx patients (51/53 = 
96.2% change), and all of the lesions in patients on dialy-
sis were diagnosed in subjects aged 50 years and older.
In the group of KTx patients, the first diagnosis of 
NMSC occurred 2–170 months (median: 74 months) 
post-transplant surgery and this time did not differ sig-
nificantly between BCC and SCC (p = 0.7). In the group of 
dialysis patients, the median time from the start of renal 
replacement therapy to the diagnosis of the first BCC was 
77 months and 132 months for SCC.
Discussion
The available literature data indicate that the most 
frequently observed skin cancers among patients after 
KTx are SCC and BCC [12, 16, 17]. Imko, in their study of 
KTx patients performed in the Gdansk region, found an 
almost 205-fold increase in the incidence rate of skin 
cancers in comparison to the general population [18]. 
According to the available literature, the risk of post-
transplantation skin cancer in the Nordic countries is up 
to 100 times greater than in the general population, and 
even up to 250 times higher in Australia, especially in the 
case of SCC [19, 20].
In our study, the incidence of NMSC was higher in 
post-transplantation patients as compared with the dial-
ysis population. Due to the insignificant number of com-
pleted studies on skin cancers comparing dialyzed and 
post-transplant patients, we encountered difficulties in 
concluding whether other studies corroborate our results 
[14, 21, 22]. Although the increased incidence of NMSC in 
patients with transplanted organs is well documented, 
there are limited data on skin cancer in dialyzed patients 
[16, 23]. In a study by Birkeland et al. [13], patients on 
dialysis and post-KTx had a higher incidence of skin can-
cer as compared to the general population. We observed 
non-significant differences in patients’ age between the 
two groups (p = 0.14) at the time of the first skin cancer 
diagnosis. The mean age of post-transplant patients at 
the time of first diagnosis of skin cancer was 59.0 ±8.4 
and did not differ from the mean age of the patients in-
cluded in the study by the Czech researchers; however, it 
was higher than the age of the patients seen in Imko’s 
study and in studies by other authors [16, 18, 24, 25].
In our study, more than one new case of skin cancer 
was diagnosed in 56% of patients with NMSC. Similar re-
sults were obtained in the studies conducted by the Ex-
pert Group on Renal Transplantation [26]; while in Imko’s 
study, only 22.5% of patients had multiple lesions [18]. The 
development of new lesions was observed to occur ap-
proximately 24 months (range: 2–60 months) later than 
in other studies, where new changes occurred on aver-
age only after 5 months [18, 27]. Unlike most studies by 
other authors [19, 28], we showed a higher incidence of 
BCC compared to SCC, and gender neutrality against the 
incidence of skin cancers in KTx patients. Results similar to 
ours were also obtained by a Spanish group [29].
The incidence of KS in the post-transplant group 
of patients is 80–500 times higher than in the general 
population [12, 30]. The highest incidence is seen in 
Saudi Arabia – 5.2% of transplant recipients [12], while 
in the United States the incidence does not exceed 0.5% 
[31]. No accurate data exist on the occurrence of KS in 
the Polish transplant recipients. In our group of 486 pa-
tients who underwent KTx, we observed two cases of KS 
(0.41%), while in another retrospective-prospective Polish 
study from Gdansk, involving a group of 830 renal trans-
plant patients, no single case of KS was found [18]. In 
the available literature, similarly to our study, KS is more 
likely to develop in males [12]. Lesions were observed 
2 and 9 months post-transplantation, consistently with 
previous observations which showed that most of the 
changes appear within 2 years after transplantation 
[30, 32]. 
Table 2. Numbers and percentages of neoplastic skin changes
Type of changes Neoplastic changes in kidney transplant patients 
(N = 58)
Neoplastic changes in dialyzed patients
 (N = 8)
P-value*
NMSC: 53 (91.4%) 8 (100%) 1.0
BCC 39 (67.2%) 7 (87.5%) 0.7
SCC 13 (22.4%) 1 (12.5%) 0.7
Bowen disease 1 (1.7%) 0 –
Merkel cell carcinoma 1 (1.7%) 0 –
Malignant melanoma 1 (1.7%) 0 –
Kaposi sarcoma 2 (3.4%) 0 –
Fibrosarcoma protuberans 1 (1.7%) 0 –
*Fisher’s test.
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In comparison to the results of a study by Piselli et al. 
[30], in which patients’ age in cases of KS ranged from 
40 to 59 years, the patients in our study were older, with 
average age of 51 years. In 60–90% of KS cases, the le-
sions are restricted to the skin [33, 34], which was con-
firmed by the results of our research. In case of internal 
organ involvement, which was not observed in this study, 
the changes are most commonly localized in the lymph 
nodes, gastrointestinal tract and lungs [35]. 
The available literature still questions whether there 
is an increased risk of malignant melanoma (MM) in 
post-organ transplantation patients. To date, in the larg-
est study performed by Lindelöf et al. [20] during a 24-
year observation period of 5,356 patients, only 6 cases 
of MM were diagnosed. Based on these findings, it is 
considered that the risk of MM in transplant patients is 
comparable to that of the general population. However, 
according to other authors, the risk is 2–8 times higher 
[9, 18, 19, 28]. In our study group, we identified only one 
case of MM, which accounted for 0.2% of all patients. 
Analysis of 89 cases of MM in patients from 14 trans-
plant centers working together in the SCOPE (Skin Care 
in Organ Transplant Recipients, Europe) showed that the 
average time from organ transplantation to the develop-
ment of MM was 8.7 years. In our patient, the lesion was 
found on the left lower extremity, at the age of 58 years, 
10 years after transplantation. 
There are no conclusive data determining the inci-
dence of MCC in post-transplant patients in the available 
literature [36]. In a study of 10,955 patients after trans-
plantation conducted by the Cincinnati Transplant Tumor 
Registry (CTTR), MCC was diagnosed in 0.37% of patients 
[37], whereas in our group in 0.2%, and in other studies, 
it occurred in 0.085% [38] and 0.071% [36] of patients. 
According to the literature, MCC appeared on average 
seven years post transplantation (0.4–25 years) and was 
usually localized on the skin exposed to sunlight [37–39]. 
In our case, MCC was diagnosed in a 61-year-old female, 
at 15 months post KTx and was localized on the buttocks. 
The time from the appearance of the lesion to the distant 
metastases (liver and periaortic lymph nodes) and pa-
tient’s death was over 9 months.
Fibrosarcoma protuberans occurred in a 17-year-old 
male at the permanent catheter exit site. Fibrosarcoma 
protuberans localization, as previously described in the 
literature, at the arterio-venous fistula can support the 
hypothesis that an injury may play a role in the patho-
genesis of this disease [40].
Conclusions
The conducted study demonstrated a significantly 
higher occurrence of skin cancers among transplant re-
cipients as compared to dialyzed patients. Interestingly, 
after analyzing the number of cases of particular types of 
skin cancer in patients receiving immunosuppression, in 
contrast to most previously published papers from West-
ern Europe and Australia, we found a higher incidence 
of basal-cell carcinoma than squamous-cell carcinoma.
Our study confirmed that the initiated dermatological 
screening program among patients on renal replacement 
therapy is very helpful for early diagnosis of neoplastic 
skin lesions. This seems particularly important in the 
view of the constantly growing number of organ trans-
plant patients. 
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